Cassava Sciences reported $9.39M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Amgen USD 5.69B 6B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cassava Sciences USD 9.39M 1.78M Jun/2026
Eisai JPY 218.93B 9.33B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Geron USD 54.46M 15.67M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026